Safety and Performance of OptiVantage, a CT Contrast Media Injector, in Multi-Patient Mode

Angela Tirri,1 Filippo Nicolò Iannelli,2 Anthony Sequeira,3 Frantz Hebert3 1Studio Medico Associato Dott.ssa Tirri Angela sas, Licata, Italy; 2Centri Iannelli Diagnosi, - Barcellona Pozzo di Gotto ME, Messina, Italy; 3Clinical Development Department, Guerbet, Roissy CDG, FranceCorrespondence: Frantz Hebert, Guerbet, BP57400, Roissy CDG Cedex, 95943, France, Email [email protected]: To evaluate the safety, performance and user’s satisfaction of OptiVantage®, a dual head CT Contrast Delivery System, in multi-patient mode for patients requiring a contrast-enhanced CT examination.Patients and Methods: A total of 100 subjects were included in this multicentre observational clinical investigation, conducted between April 20, 2023, and October 6, 2023. The primary endpoint for safety was the rate of extravasation, and the primary endpoint for performance was the success of injection assessed by the investigator. Secondary endpoints for safety were the rates of air embolism and sepsis as well as adverse events (AE) related to the injection. Other data collected included indication, set-up time, injection parameters and user’s satisfaction.Results: The study population included 59% of women. The mean age was 63.6 ± 12.7 years (range: 18 to 83 years), with the majority of patients (55%) older than 65 years. The main indications for undergoing contrast-enhanced CT were breast cancer, colon cancer and lung cancer or nodules. The mean volume injected was 119.5 ± 14.4 mL and the injection rate ranged from 2.8 to 4.5 mL/s (mean; 3.6 ± 0.3 mL/s). No extravasation or other adverse event, including air embolism and sepsis, was reported in any of the subjects (95% CI: [0.00%, 3.62%]). All the injections (100%; 95% CI: 95.39%, 100.00%) were considered as successful for the obtention of diagnostic images. The preparation of the subject, including the setting of the patient line, took between 6 and 10 seconds in most cases (68%) and 16 to 20 seconds for 30 patients (30%). The dayset was changed for 15 subjects and in all cases, it took no more than one minute.Conclusion: In conclusion, this study confirms the safety and performance of the OptiVantage® Dual head in multi-use mode for contrast injection in adult patients, particularly elderly, undergoing contrast-enhanced CT.Keywords: power injector, contrast medium, efficiency, usability, safety, elderly

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-04-01
Primary Topic
Chemotherapy-related skin toxicity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and Performance of OptiVantage, a CT Contrast Media Injector, in Multi-Patient Mode

SHILAP Revista de lepidopterología
Chemotherapy-related skin toxicity
article

Safety and Performance of OptiVantage, a CT Contrast Media Injector, in Multi-Patient Mode

article en

Abstract

Angela Tirri,1 Filippo Nicolò Iannelli,2 Anthony Sequeira,3 Frantz Hebert3 1Studio Medico Associato Dott.ssa Tirri Angela sas, Licata, Italy; 2Centri Iannelli Diagnosi, - Barcellona Pozzo di Gotto ME, Messina, Italy; 3Clinical Development Department, Guerbet, Roissy CDG, FranceCorrespondence: Frantz Hebert, Guerbet, BP57400, Roissy CDG Cedex, 95943, France, Email [email protected]: To evaluate the safety, performance and user’s satisfaction of OptiVantage®, a dual head CT Contrast Delivery System, in multi-patient mode for patients requiring a contrast-enhanced CT examination.Patients and Methods: A total of 100 subjects were included in this multicentre observational clinical investigation, conducted between April 20, 2023, and October 6, 2023. The primary endpoint for safety was the rate of extravasation, and the primary endpoint for performance was the success of injection assessed by the investigator. Secondary endpoints for safety were the rates of air embolism and sepsis as well as adverse events (AE) related to the injection. Other data collected included indication, set-up time, injection parameters and user’s satisfaction.Results: The study population included 59% of women. The mean age was 63.6 ± 12.7 years (range: 18 to 83 years), with the majority of patients (55%) older than 65 years. The main indications for undergoing contrast-enhanced CT were breast cancer, colon cancer and lung cancer or nodules. The mean volume injected was 119.5 ± 14.4 mL and the injection rate ranged from 2.8 to 4.5 mL/s (mean; 3.6 ± 0.3 mL/s). No extravasation or other adverse event, including air embolism and sepsis, was reported in any of the subjects (95% CI: [0.00%, 3.62%]). All the injections (100%; 95% CI: 95.39%, 100.00%) were considered as successful for the obtention of diagnostic images. The preparation of the subject, including the setting of the patient line, took between 6 and 10 seconds in most cases (68%) and 16 to 20 seconds for 30 patients (30%). The dayset was changed for 15 subjects and in all cases, it took no more than one minute.Conclusion: In conclusion, this study confirms the safety and performance of the OptiVantage® Dual head in multi-use mode for contrast injection in adult patients, particularly elderly, undergoing contrast-enhanced CT.Keywords: power injector, contrast medium, efficiency, usability, safety, elderly

SHILAP Revista de lepidopterología
Openalex Percentile: Top 31%
Chemotherapy-related skin toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.